​

Funding Round

Series B - Passage Bio

Series B - Passage Bio

Investment Firm

Overview

Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.

Announced Date

Sep 04, 2019

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Access Biotechnology

Access Biotechnology

Access Biotechnology is a early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.

Participant Investors

10

Investor Name
Participant InvestorAccess Biotechnology
Participant InvestorLilly Asia Ventures
Participant InvestorVersant Ventures
Participant InvestorFrazier Healthcare Partners
Participant InvestorVivo Capital

Round Details and Background

Passage Bio raised $110000000 on 2019-09-04 in Series B

Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Feb 15, 2019
Series A - Passage Bio
6-115.5M
Sep 04, 2019
Series B - Passage Bio
11-110.0M
Jan 21, 2021
Post-IPO Equity - Passage Bio
-154.0M

Recent Activity

There is no recent news or activity for this profile.